News articles about Concert Pharmaceuticals (NASDAQ:CNCE) have trended positive recently, Accern Sentiment reports. Accern identifies positive and negative press coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Concert Pharmaceuticals earned a news impact score of 0.25 on Accern’s scale. Accern also gave news headlines about the biotechnology company an impact score of 46.9993857910966 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.
Shares of Concert Pharmaceuticals (NASDAQ:CNCE) traded up 0.20% during midday trading on Friday, hitting $14.76. The stock had a trading volume of 55,737 shares. Concert Pharmaceuticals has a 52 week low of $7.11 and a 52 week high of $19.11. The stock has a 50-day moving average of $14.62 and a 200 day moving average of $14.79. The stock’s market cap is $334.86 million.
Concert Pharmaceuticals (NASDAQ:CNCE) last issued its quarterly earnings results on Tuesday, August 8th. The biotechnology company reported ($0.58) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.62) by $0.04. Concert Pharmaceuticals had a negative net margin of 60,681.70% and a negative return on equity of 61.98%. The company had revenue of $0.02 million during the quarter, compared to the consensus estimate of $0.20 million. Analysts anticipate that Concert Pharmaceuticals will post ($2.18) EPS for the current fiscal year.
Several brokerages recently weighed in on CNCE. HC Wainwright reaffirmed a “buy” rating and set a $20.00 target price on shares of Concert Pharmaceuticals in a report on Wednesday, August 9th. Zacks Investment Research raised Concert Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Thursday, August 10th. BidaskClub lowered Concert Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Wednesday, July 12th. ValuEngine raised Concert Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Friday, June 23rd. Finally, Aegis reaffirmed a “buy” rating and set a $25.00 target price on shares of Concert Pharmaceuticals in a report on Monday, June 12th. One analyst has rated the stock with a sell rating, one has issued a hold rating and five have given a buy rating to the company. The stock has a consensus rating of “Buy” and a consensus price target of $24.80.
Concert Pharmaceuticals Company Profile
Concert Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of small molecule drugs. The Company operates through the development of pharmaceutical products on its own behalf or in collaboration with others. The Company’s deuterated chemical entity platform (DCE Platform), has potential across various therapeutic areas.
Receive News & Ratings for Concert Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Concert Pharmaceuticals Inc. and related companies with our FREE daily email newsletter.